Shots:

• The P-III (DREAMS-1) study assessed mazdutide (4mg, 6mg) vs PBO to treat T2D Chinese patients (n=320) with insufficient glycemic control for 24wks. after which, PBO group was switched to 6mg for another 24wks. NDA to the NMPA is planned for the same
• Study, at 24wks., showed reduced HbA1c of 1.57% & 2.15% vs 0.14% that sustained till 48wks.; no. of patients attaining HbA1c<7.0%, wt. reduction ≥5% plus dual targets (HbA1c<7% & wt. reduction ≥5%) were more in mazdutide group
• Furthermore, wt. loss of 9.6% at wk.48 was seen with 6mg. Reduction in cardiovascular metabolic indicators such as postprandial blood glucose, waist circumference, blood pressure, blood lipids, transaminases & urinary albumin-to-creatinine ratio were also observed

Ref: Innovent | Image: Innovent

Related News:- Innovent Biologics Reports the P-III Trial Results of Mazdutide for Treating Type 2 Diabetes

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com